Floatz Rating
C39/100
Confidence
Indicative
Sponsor
University of California, Los Angeles
Modality
Small molecule
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Indicative
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Interstitial Lung Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fapi-46 (this asset) | University of California, Los Angeles | Early P1 | C · 39 |
| Prednisone | National Institute for Tuberculosis and Lung Diseases, Poland | P4 | BB |
| Uniprost | United Therapeutics | P3 | BB |
| Cyclophosphamide | Intergroupe Francophone de Cancerologie Thoracique | P2/3 | B |
| Sildenafil | University of California, Los Angeles | P4 | B |
| Rituximab | Royal Brompton & Harefield NHS Foundation Trust | P2/3 | B |
| Bardoxolone Methyl Ester | Biogen | P2 | B |
| Alpha-Interferon | Texas Tech University Health Sciences Center | P2 | B |
| Bosentan | Royal Brompton & Harefield NHS Foundation Trust | P4 | B |
+26 more in the Interstitial Lung Disease cohort
Other indications for Fapi-46
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cholangiocarcinoma | — | P2 | CCC · 55 |
| Melanoma | — | P2 | CCC · 53 |
| Amyloidosis | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fapi-46 in Interstitial Lung Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fapi-46-interstitial-lung-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →